Analytical Data
-
基因名
Claudin-6/CLDN6
-
简介
Claudin-6/CLDN6 Protein-VLP is pivotal in targeted elimination of intercellular spaces within tight junctions, ensuring cell barrier integrity and polarity. Moreover, it serves as a receptor for hepatitis C virus (HCV), facilitating viral entry into hepatic cells. Claudin-6/CLDN6 Protein, Human (sf9, His, Twin-Strep, Nanodisc) is the recombinant human-derived Claudin-6/CLDN6 protein, expressed by sf9 insect cells, with C-Twin-Strep and N-His labeled tag.
- Application
-
别名
Claudin-6; Skullin; CLDN6; Claudin6; Skullin 2
-
种属
Human
-
表达系统
Baculovirus
-
标签
C-Twin-Strep;N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P56747
-
表达区间
M1-V220
-
蛋白长度
Full Length
-
分子量
23-28 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Claudin-6 (CLDN6) is a member of the claudin family of proteins, which play crucial roles in the formation and maintenance of tight junctions between epithelial cells. These tight junctions are essential for regulating paracellular permeability and maintaining tissue integrity. Research has shown that CLDN6 is highly expressed in certain cancers, including germ cell tumors and various carcinomas, making it a potential biomarker and therapeutic target. The recombinant expression of CLDN6 has enabled scientists to study its structural and functional properties in detail. Previous studies suggest that CLDN6 might also be involved in signaling pathways that govern cell proliferation and differentiation. Additionally, its unique expression pattern in certain malignancies provides opportunities for targeted therapies, such as monoclonal antibodies or CAR-T cell approaches. The development of CLDN6 recombinant proteins has advanced our understanding of its role in cancer biology and tight junction dynamics and offers promising avenues for diagnostic and therapeutic strategies in oncology. Through the generation of CLDN6 fusion proteins, researchers aim to elucidate its mechanisms of action and explore its potential as a target for clinical interventions in cancer treatment.
